Prism AI Therapeutics
Jason Friske, CPA, serves as the Fractional VP Finance at Prism AI and Managing Member at NLJ Consulting, specializing in financial consulting, bookkeeping, and system design for early-stage startups. Previously, Jason held the position of VP Finance at Veracyte, Inc. during a post-merger integration period, and at C2i Genomics, where Jason organized efforts leading to a successful company sale. Prior roles include Senior Controller at Opentrons Labworks Inc., contributing to significant funding efforts and financial system migrations, and VP of Finance at Undertone, overseeing extensive revenue budgets and cost-saving initiatives. Additional experience includes a Vice President role at MakerBot®, where Jason managed an accounting team and facilitated operational shifts. Jason holds a BS in Accounting from Montclair State University and has background experience in computer science from Rutgers University.
This person is not in the org chart
This person is not in any teams
Prism AI Therapeutics
Prism AI Therapeutics, Inc., offers an AI-first clinical multi-omic data management and analytics platform that allows biotech companies and health systems to unlock the value of their own data and create the next generation of drugs and biomarkers. Backed by partnerships with pharmaceutical and diagnostic companies, and with a clear mission to accelerate the development and implementation of precision therapeutics, we are poised to make a significant impact. The ability to detect and target complex multi-omic differential signatures is the basis for personalized medicine. But typical AI cannot discover effective biomarkers from real-life clinical trial data. Our cloud computing platform provides a powerful and novel AI approach for the discovery of biomarkers, companion diagnostics (CDx), and drug targets from raw, real-life, small-cohort, multi-omic, and noisy clinical data, with label-free (unsupervised) batch effect correction and data harmonization among multiple sites, demographic variables, measurement platforms, and collection protocols. Our patented technology, based on quantum mechanics, has produced multiple novel oncology biomarkers that have been clinically proven to be the most accurate and precise in peer-reviewed publications. Let’s partner up to cure the most devastating diseases!